Sameh M Abdel Monem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sameh M Abdel Monem has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Essam Wahab
2 shared publicationsTalaat Fathy
Department of Tropical Medicine Zagazig University Hospitals Zagazig Egypt
2 shared publicationsAbdelmonem M Elshamy
Tropical Medicine Department, Faculty of Medicine,Zagazig University, Zagazig, Egypt
1 shared publication- Emad Fawzi Hamed
Zagazig University, Internal Medicine Department, Faculty of Medicine, Zagazig, Egypt
1 shared publication Emad Moustafa
1 shared publicationEssam A Wahab
Department of Internal Medicine
1 shared publication
Latest Publications
- 10 August 2020
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
Prevalence and Predictors of Occult Hepatitis C Infection in High-Risk Egyptian Populations
Background and study aim: Direct acting antiviral agents (DAAs) altered hepatitis C virus (HCV) outcomes with a permanent cure in 90% of cases. However, HCV had not wiped out from all cases (1% ~ 15%), which represent occult HCV infection (OCI). The aim of this study is todetect prevalence and predictors of OCI in four high-risk groups. Patients and Methods: 196 participants were enrolled and assigned into four patients groups and one control group; group I (cryptogenic hepatitis), group II (HCV), group III (chronic HBV), group IV (ESRD), and group V (control group). HCV RNA testing in serum and in peripheral blood mononuclear cells, hepatic stiffness estimation and FIB-4 score calculation were done for all participants. Results: Significant differences were found among different study groups regarding frequencies of HTN (p<0.001) and DM (p<0.001), history of blood transfusion (p<0.001), history of previous surgery (p<0.001), as well as mean values of FIB-4 (p<0.001) and fibroscan readings (p=0.002). OCI was found in 25 participants (12.7%), with different prevalence rates in different groups; being highest in group I (11/43, 25.3%), followed by group III (6/30, 20%). Among all participants, OCI was significantly associated multiple risk factors that include; history of blood transfusion (p=0.004), previous surgery (p=0.017), positive family history of HCV infection (p<0.001), advanced fibrosis (p =0.015) and high FIB-4 score (p=0.016). Positive family history of HCV infection and history of blood transfusion were considered as independent predictors for OCI. Conclusion: Testing for OCI in high-risk populations and retesting in SVR cases might be needed to help in complete eradication of chronic HCV infection.
- 10 August 2020
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
Prevalence and Predictors of Occult Hepatitis C Infection in High-Risk Egyptian Populations
Background and study aim: Direct acting antiviral agents (DAAs) altered hepatitis C virus (HCV) outcomes with a permanent cure in 90% of cases. However, HCV had not wiped out from all cases (1% ~ 15%), which represent occult HCV infection (OCI). The aim of this study is todetect prevalence and predictors of OCI in four high-risk groups. Patients and Methods: 196 participants were enrolled and assigned into four patients groups and one control group; group I (cryptogenic hepatitis), group II (HCV), group III (chronic HBV), group IV (ESRD), and group V (control group). HCV RNA testing in serum and in peripheral blood mononuclear cells, hepatic stiffness estimation and FIB-4 score calculation were done for all participants. Results: Significant differences were found among different study groups regarding frequencies of HTN (p<0.001) and DM (p<0.001), history of blood transfusion (p<0.001), history of previous surgery (p<0.001), as well as mean values of FIB-4 (p<0.001) and fibroscan readings (p=0.002). OCI was found in 25 participants (12.7%), with different prevalence rates in different groups; being highest in group I (11/43, 25.3%), followed by group III (6/30, 20%). Among all participants, OCI was significantly associated multiple risk factors that include; history of blood transfusion (p=0.004), previous surgery (p=0.017), positive family history of HCV infection (p<0.001), advanced fibrosis (p =0.015) and high FIB-4 score (p=0.016). Positive family history of HCV infection and history of blood transfusion were considered as independent predictors for OCI. Conclusion: Testing for OCI in high-risk populations and retesting in SVR cases might be needed to help in complete eradication of chronic HCV infection.
- 13 June 2020
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
- p. 237-244
Cardiac Changes in Cirrhotic Patients
- 13 June 2020
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
- p. 237-244
Cardiac Changes in Cirrhotic Patients
- Open Access
Conscious sedation using propofol versus midazolam in cirrhotic patients during upper GI endoscopy: A comparative study
Aim: We aimed to assess the safety and efficacy of propofol versus midazolam in cirrhotic patients undergoing upper GI endoscopy.Methods: Ninety compensated cirrhotic patients (all met class I–III criteria according to the American Society of Anesthesia) were enrolled in this comparative study. They were classified into three groups according to scheduled pre‐endoscopy sedation drugs; the midazolam group, which included 30 patients who received IV weight‐dependent midazolam (0.05 mg/kg with additional doses of 1 mg every 2 min when necessary, up to a maximum dose of 0.1 mg/kg or 10 mg); the propofol group, which included 30 patients who received a propofol bolus dose according to age and weight (0.25 mg/kg with additional doses of 20–30 mg every 30–60 s when necessary, up to a maximum dose of 400 mg); and the combined group, which included 30 patients who received half a dose of midazolam and of propofol.Results: Prolonged postendoscopy recovery times were reported in the midazolam group, while shorter recovery times were reported in the propofol and combined groups. All patients in the propofol and combined groups gained consciousness shortly postendoscopy; however, only half of the midazolam group's patients gained consciousness after the standard recovery time (10–30 min). Highly significant differences were found among the three groups regarding consciousness level according to the Glasgow coma scale, as well as regarding the occurrence of hypoxia during endoscopy.Conclusion: Considering safety and efficacy issues, propofol is better than midazolam in gastrointestinal endoscopy, especially in patients with liver cirrhosis.
Open AccessConscious sedation using propofol versus midazolam in cirrhotic patients during upper GI endoscopy: A comparative study
Aim: We aimed to assess the safety and efficacy of propofol versus midazolam in cirrhotic patients undergoing upper GI endoscopy.Methods: Ninety compensated cirrhotic patients (all met class I–III criteria according to the American Society of Anesthesia) were enrolled in this comparative study. They were classified into three groups according to scheduled pre‐endoscopy sedation drugs; the midazolam group, which included 30 patients who received IV weight‐dependent midazolam (0.05 mg/kg with additional doses of 1 mg every 2 min when necessary, up to a maximum dose of 0.1 mg/kg or 10 mg); the propofol group, which included 30 patients who received a propofol bolus dose according to age and weight (0.25 mg/kg with additional doses of 20–30 mg every 30–60 s when necessary, up to a maximum dose of 400 mg); and the combined group, which included 30 patients who received half a dose of midazolam and of propofol.Results: Prolonged postendoscopy recovery times were reported in the midazolam group, while shorter recovery times were reported in the propofol and combined groups. All patients in the propofol and combined groups gained consciousness shortly postendoscopy; however, only half of the midazolam group's patients gained consciousness after the standard recovery time (10–30 min). Highly significant differences were found among the three groups regarding consciousness level according to the Glasgow coma scale, as well as regarding the occurrence of hypoxia during endoscopy.Conclusion: Considering safety and efficacy issues, propofol is better than midazolam in gastrointestinal endoscopy, especially in patients with liver cirrhosis.
- 1 September 2018
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
- Vol. 8 (3) , 140-148
Serum Resistin Level as a Diagnostic Marker in Non-Alcoholic Steatohepatitis
- 1 September 2018
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
- Vol. 8 (3) , 140-148
Serum Resistin Level as a Diagnostic Marker in Non-Alcoholic Steatohepatitis
- 1 June 2018
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
- Vol. 8 (2) , 68-73
Cardiac Parameters and Interleukin-6 Differences between Adolescents with Hepatitis B Infection versus those Complicated with Hepatocelluar Carcinoma
Background and study aim: Hepatitis B virus (HBV) is a major risk factor of hepatocellular carcinoma (HCC) in all age groups. There is a need to differentiate between them in the adolescence age by laboratory and physical examination for assessment of different outcomes of both diseases. Subjects and Methods: Cross sectional study that included Session [UserIDID] adolescents with HBV, another Session [UserIDID] with HCC with age ranging from 12 and up to 17 years. They were selected from those admitted to Tropical Medicine Department, Menofia University and Tropical Medicine Department, Zagazig University. All patient underwent laboratory assessment of interleukin6 (IL6) and were further examined at the Cardiology Unit in Pediatric department of Ain Shams University hospitals for complete echo-cardiographic and anthropometric evaluation. Results: Twenty four patients have HCC were examined with mean age (14.15± 3.01) years and another Session [UserIDID] are having HBV (14.64±3.13) years. Differences were found between both groups as regards IL6 as mean values were (13.29 pg/ml) in HBV and (77.63 pg/ml) in HCC group while no differences were detected as regards cardiac and anthropometric evaluations. Conclusion: IL6 seems to be a useful marker to compare between HBV and HCC in adolescent patients instead of depending on clinical cardiac evaluation or growth parameters that showed no differences.
- 1 June 2018
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
- Vol. 8 (2) , 68-73
Cardiac Parameters and Interleukin-6 Differences between Adolescents with Hepatitis B Infection versus those Complicated with Hepatocelluar Carcinoma
Background and study aim: Hepatitis B virus (HBV) is a major risk factor of hepatocellular carcinoma (HCC) in all age groups. There is a need to differentiate between them in the adolescence age by laboratory and physical examination for assessment of different outcomes of both diseases. Subjects and Methods: Cross sectional study that included Session [UserIDID] adolescents with HBV, another Session [UserIDID] with HCC with age ranging from 12 and up to 17 years. They were selected from those admitted to Tropical Medicine Department, Menofia University and Tropical Medicine Department, Zagazig University. All patient underwent laboratory assessment of interleukin6 (IL6) and were further examined at the Cardiology Unit in Pediatric department of Ain Shams University hospitals for complete echo-cardiographic and anthropometric evaluation. Results: Twenty four patients have HCC were examined with mean age (14.15± 3.01) years and another Session [UserIDID] are having HBV (14.64±3.13) years. Differences were found between both groups as regards IL6 as mean values were (13.29 pg/ml) in HBV and (77.63 pg/ml) in HCC group while no differences were detected as regards cardiac and anthropometric evaluations. Conclusion: IL6 seems to be a useful marker to compare between HBV and HCC in adolescent patients instead of depending on clinical cardiac evaluation or growth parameters that showed no differences.
- 1 March 2018
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
- Vol. 8 (1) , 48-54
Role of Hepatitis C Virus Core Antigen Assay in Blood Donors Screening at Zagazig University Hospitals
- 1 March 2018
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
- Vol. 8 (1) , 48-54
Role of Hepatitis C Virus Core Antigen Assay in Blood Donors Screening at Zagazig University Hospitals
- Open Access
- 1 June 2017
- Published by Jaypee Brothers Medical Publishing in Euroasian Journal of Hepato-Gastroenterology
- Vol. 7 (1) , 101-106
Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals
Aim: Nonalcoholic fatty liver disease (NAFLD) is probably the most common liver disorder in the world. A subgroup of NAFLD patients is characterized by injury to the hepatocytes and inflammation in addition to excessive fat (steatohepatitis), the latter condition is nominated nonalcoholic steatohepatitis (NASH). This work aimed to evaluate the role of probiotics on the outcome of NASH in patients admitted to the Tropical Medicine Department, Faculty of Medicine, Zagazig University (inpatients and outpatients). Materials and methods: This study was performed on 30 patients (17 males and 13 females), with body mass index from 30 to 35 and average age of 44 years with bright fatty liver in ultrasonography and raised alanine transaminase (ALT) and aspartate transaminase (AST) and positive liver biopsy findings. The patients were divided into group I (case group) that included 15 patients who received probiotics and group II of 15 patients as control group who did not receive probiotics; the study was conducted between November 2014 and April 2016. Clinical assessment, laboratory evaluation, pelvic-abdominal ultrasound, and liver biopsy of all cases were carried out. Results: In this study, there was significant decrease in liver enzymes (ALT and AST) and no statistically significant other laboratory findings. Also there was relief for dyspepsia in some patients. Conclusion: Probiotics treatment is effective, safe, well-tolerated, inexpensive, appropriate for long-term use, and optimally, works at multiple levels to downregulate inflammatory mediators, and therefore, probiotics could be an option in the treatment of NASH. How to cite this article: Monem SMA. Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals. Euroasian J Hepato-Gastroenterol 2017;7(1):101-106.
- 1 June 2017
- Published by Jaypee Brothers Medical Publishing in Euroasian Journal of Hepato-Gastroenterology
- Vol. 7 (1) , 101-106
Open AccessProbiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals
Aim: Nonalcoholic fatty liver disease (NAFLD) is probably the most common liver disorder in the world. A subgroup of NAFLD patients is characterized by injury to the hepatocytes and inflammation in addition to excessive fat (steatohepatitis), the latter condition is nominated nonalcoholic steatohepatitis (NASH). This work aimed to evaluate the role of probiotics on the outcome of NASH in patients admitted to the Tropical Medicine Department, Faculty of Medicine, Zagazig University (inpatients and outpatients). Materials and methods: This study was performed on 30 patients (17 males and 13 females), with body mass index from 30 to 35 and average age of 44 years with bright fatty liver in ultrasonography and raised alanine transaminase (ALT) and aspartate transaminase (AST) and positive liver biopsy findings. The patients were divided into group I (case group) that included 15 patients who received probiotics and group II of 15 patients as control group who did not receive probiotics; the study was conducted between November 2014 and April 2016. Clinical assessment, laboratory evaluation, pelvic-abdominal ultrasound, and liver biopsy of all cases were carried out. Results: In this study, there was significant decrease in liver enzymes (ALT and AST) and no statistically significant other laboratory findings. Also there was relief for dyspepsia in some patients. Conclusion: Probiotics treatment is effective, safe, well-tolerated, inexpensive, appropriate for long-term use, and optimally, works at multiple levels to downregulate inflammatory mediators, and therefore, probiotics could be an option in the treatment of NASH. How to cite this article: Monem SMA. Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals. Euroasian J Hepato-Gastroenterol 2017;7(1):101-106.